Current Pharmacotherapy of Non-Small Cell Lung Cancer

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorSrinivasan, Sankara Narayanan
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentHalasi, Barbara Dóra
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2023-05-03T08:30:05Z
dc.date.available2023-05-03T08:30:05Z
dc.date.created2023
dc.description.abstractNon-small cell lung cancer (NSCLC) is a prevalent form of lung cancer and a significant cause of cancer-related mortality worldwide. It constitutes approximately 80-85% of all lung cancer cases. Diagnosis of NSCLC entails imaging studies and biopsy procedures to assess the tumour's size, location, and extent. Subsequently, the disease is staged based on various criteria, including the scope of local invasion, regional lymph node involvement, and distant metastasis. Chemotherapy remains a cornerstone of NSCLC treatment, and platinum-based combination regimens are the most widely used. Targeted therapy is a rapidly developing field that exploits specific genetic alterations or protein overexpression in tumour cells as therapeutic targets, with drugs targeting EGFR, ALK, and ROS1 mutations showing efficacy in patients with these alterations. Immune checkpoint inhibitors represent a recent advance in the treatment of NSCLC. These drugs enhance the anti-tumour immune response by blocking inhibitory signals on immune cells, leading to a more robust immune response against cancer cells. The pharmacotherapy of NSCLC has undergone substantial advancement in recent years, with the introduction of targeted therapy and immune checkpoint inhibitors offering promising new avenues for treatment. However, considering the patient’s and tumour's unique characteristics, a personalised treatment approach is crucial for maximising therapeutic benefit and minimizing toxicity.
dc.description.correctorLB
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent41
dc.identifier.urihttps://hdl.handle.net/2437/351557
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectNSCLC
dc.subjectNon-small cell lung cancer
dc.subjectChemotherapy
dc.subjectTargeted therapy
dc.subjectImmunotherapy
dc.subjectPlatinum-based combination regimens
dc.subjectEGFR
dc.subjectALK
dc.subjectROS1
dc.subjectImmune checkpoint inhibitors
dc.subjectPD-L1
dc.subjectPD-1
dc.subjectPersonalized treatment
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titleCurrent Pharmacotherapy of Non-Small Cell Lung Cancer
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)